

Novacyt S.A.

("Novacyt" or the "Company")

Publication of Annual Report

Paris, France and Camberley, UK – 29 June 2021 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company's Annual Report and Accounts ("Annual Report") for the year ended 31 December 2020 has been published and uploaded to the Company's website. The Annual Report has been posted to all shareholders that hold ordinary shares through CREST Depository Interests (CDIs).

It is intended that the Company's Annual General Meeting ("AGM") will be held in September 2021 further details of which will be provided to shareholders in due course.

An electronic copy of the Annual Report is available on the Company's website at www.novacyt.com. Alternatively, a hard copy is available from Unit 1, Watchmoor Point, Watchmoor Road, Camberley, Surrey, GU15 3AD.

- End -

Novacyt SA

Graham Mullis, Chief Executive Officer
James McCarthy, Chief Financial Officer
+44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black
+44 (0)20 7260 1000

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw
+44 (0)20 3727 1000


victoria.fostermitchell@fticonsulting.com / alex.shaw@fticonsulting.com /
Novacyt.group@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines
+33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of *in vitro* and molecular diagnostic tests. Its core strengths lie in diagnostics



NOVACYT

GROUP

product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website: www.novacyt.com